We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+8.65%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$6.63B
AUM Growth
+$825M
Cap. Flow
+$471M
Cap. Flow %
7.11%
Top 10 Hldgs %
82.61%
Holding
140
New
29
Increased
38
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.1M
2
INCY icon
Incyte
INCY
+$10.5M
3
DNLI icon
Denali Therapeutics
DNLI
+$8.99M
4
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$7.86M
5
ALBO
Albireo Pharma Inc
ALBO
+$7.61M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$33.5M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.4M
3
RXDX
Ignyta, Inc.
RXDX
+$11.1M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$10.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.26%
2 Consumer Discretionary 19.67%
3 Healthcare 17.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUMO
101
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.62M 0.02%
22,222
– –
KRYS icon
102
Krystal Biotech
KRYS
$10.8B
$1.58M 0.02%
150,000
+50,000
+50% +$501K
EDIT icon
103
Editas Medicine
EDIT
$399M
$1.54M 0.02%
+50,000
New +$1.26M
KURA icon
104
Kura Oncology
KURA
$818M
$1.53M 0.02%
100,000
– –
NERV icon
105
Minerva Neurosciences
NERV
$195M
$1.52M 0.02%
31,413
– –
KDNY
106
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.5M 0.02%
40,000
– –
RYTM icon
107
Rhythm Pharmaceuticals
RYTM
$7.4B
$1.45M 0.02%
+50,000
New +$1.32M
SNDX icon
108
Syndax Pharmaceuticals
SNDX
$1.73B
$1.31M 0.02%
150,000
-2,920
-2% -$28.9K
CRSP icon
109
CRISPR Therapeutics
CRSP
$4.7B
$1.17M 0.02%
+50,000
New +$950K
TRIL
110
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.09M 0.02%
+150,000
New +$1.24M
VRDN icon
111
Viridian Therapeutics
VRDN
$2.17B
$1.04M 0.02%
6,667
– –
FBRX icon
112
Forte Biosciences
FBRX
$1.57B
$1.02M 0.02%
+267
New +$1.07M
IBRX icon
113
ImmunityBio
IBRX
$7.25B
$1.01M 0.02%
225,000
– –
CLDX icon
114
Celldex Therapeutics
CLDX
$2.92B
$995K 0.02%
23,356
-21,644
-48% -$927K
CALA
115
DELISTED
Calithera Biosciences, Inc
CALA
$835K 0.01%
5,000
-3,750
-43% -$960K
NVLN
116
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$800K 0.01%
256,400
– –
IMDX
117
Insight Molecular Diagnostics
IMDX
$145M
$698K 0.01%
7,500
– –
NVAX icon
118
Novavax
NVAX
$1.22B
$620K 0.01%
25,000
– –
XENE icon
119
Xenon Pharmaceuticals
XENE
$6.19B
$424K 0.01%
150,000
– –
AAL icon
120
CALL
American Airlines Group
AAL
$9.98B
– –
-500,000
Closed -$23.7M
BLK icon
121
CALL
Blackrock
BLK
$171B
– –
-50,000
Closed -$22.4M
BMRN icon
122
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-200,000
Closed -$17.4M
ELF icon
123
e.l.f. Beauty
ELF
$4.95B
– –
-200,000
Closed -$4.51M
KYNB
124
Kyntra Bio
KYNB
$27.9M
– –
-2,000
Closed -$2.69M
INTC icon
125
CALL
Intel
INTC
$434B
– –
-500,000
Closed -$19M
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2017 Portfolio in Review

As of Q4 2017, Artal Group held 140 positions worth $6.63B, up 14% from $5.81B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group deployed $471M of net new capital in Q4 2017, opening 29 new positions and adding to 38 existing holdings. Its largest new stake was Denali Therapeutics: 500,000 shares worth $7.82M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $33.5M trimmed.

  • Artal Group's largest Q4 2017 buy was Denali Therapeutics: 500,000 shares worth $7.82M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2017, an estimated $25.1M increase.
  • Artal Group's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $33.5M.
  • Artal Group fully exited BioMarin Pharmaceuticals in Q4 2017, selling an estimated $17.4M.
  • Artal Group's ten largest holdings make up 83% of its $6.63B portfolio in Q4 2017.
  • Artal Group opened 29 new positions and closed 21 in Q4 2017.
  • Artal Group's portfolio value rose 14% quarter-over-quarter to $6.63B.

Based on Artal Group's 13F filing for Q4 2017, filed 9 Feb 2018.